Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908323 · ClinicalTrials.gov registry record
Early Immune Responses to Vaccination - A Substudy to HVTN 205
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 47
- Enrollment target
NCT00908323 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 47 participants.
The verdict
NCT00908323 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.
Interventions
- BIOLOGICAL MVA/HIV62 vaccine
- BIOLOGICAL JS7 DNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908323
The ClinicalTrials.gov registry entry for NCT00908323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MVA/HIV62 vaccine is the first listed.
NCT00908323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908323 about?
NCT00908323 is a clinical study titled "Early Immune Responses to Vaccination - A Substudy to HVTN 205". HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict stro...
What is the current status of trial NCT00908323?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2009-07. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00908323?
The interventions under investigation include: MVA/HIV62 vaccine (BIOLOGICAL), JS7 DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00908323?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.